Table 3.
Fractional incidence of RP by most common postempiric antibiotic therapies
| Final Antibiotic Therapy | No. of Episodes Treated | Episodes Followed by Relapse (% [P])a | Duration of Treatment (Days; Mean ± SD [P]) |
|
|---|---|---|---|---|
| Non-RP Episodes | RP Episodes | |||
| Glycopeptide + ceftazidime | 134 | 13 (0.36) | 14.2 ± 3.4 | 14.2 ± 3.4 (0.92b) |
| First-generation cephalosporin + ceftazidime | 62 | 15 (0.28) | 13.9 ± 2.9 | 15.4 ± 3.2 (0.15b) |
| Ceftazidime | 62 | 8 (0.48) | 13.3 ± 5.0 | 14.2 ± 0.4 (0.70b) |
| First-generation cephalosporin | 57 | 18 (0.07) | 14.9 ± 6.5 | 17.0 ± 7.3 (0.37b) |
| Glycopeptide | 51 | 8 (0.50) | 15.7 ± 4.9 | 13.0 ± 2.0 (0.29b) |
| Ceftazidime + aminoglycoside | 26 | 12 (0.87) | 19.4 ± 9.1 | 27.3 ± 3.1 (0.15b) |
| Aminoglycoside | 5 | 0 (0.44) | 19.0 ± 3.4 | NA |
Antibiotic therapies with no significant frequency of use not shown.
a
Statistical significance indicates difference compared with all other postempiric antibiotic therapies.
b
Versus duration of treatment in non-RP episodes.